Head-To-Head Survey: Longevity Health (NASDAQ:XAGE) & Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ:BVS) and Longevity Health (NASDAQ:XAGE) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Risk and Volatility

Bioventus has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Longevity Health has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Institutional and Insider Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 29.0% of Longevity Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Bioventus and Longevity Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	1	0	0	0	1.00
Longevity Health	0	0	0	0	0.00

Profitability

This table compares Bioventus and Longevity Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	1.39%	26.38%	7.27%
Longevity Health	-682.67%	N/A	-261.90%

Earnings and Valuation

This table compares Bioventus and Longevity Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28 million	1.01	-$33.54 million	$0.12	58.25
Longevity Health	$1.05 million	0.86	-$10.37 million	($3.91)	-0.13

Longevity Health has lower revenue, but higher earnings than Bioventus. Longevity Health is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Summary

Bioventus beats Longevity Health on 11 of the 12 factors compared between the two stocks.

About Bioventus

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.